| Clone: | CB3-1 |
|---|---|
| Isotype: | Mouse IgG1 |
| Specificity: | The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b (CD79 beta, Ig beta), an approximately 38 kDa component of B cell receptor (BCR) complex. HLDA VI.; WS Code CD79.1 |
| Immunogen: | Fraction of Ig-associated molecules isolated from Ramos B cells |
| Species Reactivity: | Human |
| Application: |
Flow Cytometry
Immunoprecipitation
Western Blotting
|
| Purity: | > 95% (by SDS-PAGE) |
| Purification: | Purified from cell culture supernatant by protein-A affinity chromatography. |
| Concentration: | 1 mg/ml |
| Storage Buffer: | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
| Storage / Stability: | Store at 2-8°C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20°C. Avoid freeze/thaw cycles. |
| Expiration: | See vial label |
| Lot Number: | See vial label |
| Background: | CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling. |
| References: |
*Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8522-6.
*Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8(10):2937-46.
*Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for
minimal residual disease detection. Leukemia. 1999 Oct;13(10):1501-5.
*Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7.
*Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate,
anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721-9.
*Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55(3):180-3.
*D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85(5):556-7.
|
For laboratory research only, not for drug, diagnostic or other use. EXBIO Praha | Nad Safinou II 341 | 252 42 Vestec u Prahy | Czech Republic Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz |